Pulmonology

The Inner Circle Acknowledges, Rocco Terrigno, MD as a Pinnacle Lifetime Member

Retrieved on: 
Friday, December 29, 2023

MULLICA HILL, N.J., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Rocco Terrigno, MD is acknowledged as a Pinnacle Lifetime Member for his contributions to the Pulmonologist and Critical Care field.

Key Points: 
  • MULLICA HILL, N.J., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Rocco Terrigno, MD is acknowledged as a Pinnacle Lifetime Member for his contributions to the Pulmonologist and Critical Care field.
  • Dr. Rocco Terrigno a renowned pulmonologist and critical care intensivist, is making a significant impact in the field of respiratory medicine.
  • Dr. Terrigno's expertise encompasses a wide range of respiratory conditions, including cough, interstitial lung disease/sarcoid, COPD/emphysema, asthma, sleep disorders, lung nodules, pleural disease, respiratory failure, and COVID-19 pneumonia.
  • Currently, Dr. Terrigno serves as a fellowship-trained pulmonologist and critical care intensivist in the Department of Critical Care Medicine at Cooper University Hospital in Camden, New Jersey.

Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

Retrieved on: 
Wednesday, November 29, 2023

Veracyte, Inc. (Nasdaq: VCYT) announced that clinical validation data published in the journal CHEST show that the company’s Percepta Nasal Swab test determines lung cancer risk, with high accuracy, among people who currently smoke or have previously smoked and have lung nodules.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) announced that clinical validation data published in the journal CHEST show that the company’s Percepta Nasal Swab test determines lung cancer risk, with high accuracy, among people who currently smoke or have previously smoked and have lung nodules.
  • Lung nodules are an early indicator of lung cancer and are typically found using computed tomography (CT) scans.
  • Results show that the Percepta Nasal Swab test is highly accurate in identifying patients with low-risk nodules (97% sensitivity, with 40% specificity).
  • “We believe our Percepta Nasal Swab test can be paradigm-changing in the evaluation of lung cancer risk among patients with lung nodules,” said Dr. Bulman.

Savara Reports Third Quarter Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2023 and provided a business update.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2023 and provided a business update.
  • “We remain on track to report top line data from the pivotal, Phase 3 IMPALA-2 trial by the end of the second quarter 2024,” said Matt Pauls, Chair and CEO, Savara.
  • “In parallel, we are working to provide pulmonologists in the U.S. and Europe with a simple, accurate, no-cost, laboratory-based antibody blood test for aPAP.
  • As of September 30, 2023, the Company had cash, cash equivalents and short-term investments of ~$168.3 million and debt of ~$26.3 million.

Boston Medical Center to Offer First FDA-Approved Gene Therapy Treatment Program for Sickle Cell Disease

Retrieved on: 
Friday, December 8, 2023

BOSTON, Dec. 8, 2023 /PRNewswire/ -- Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will offer the first-ever gene therapy treatment program for sickle cell disease that uses a type of novel genome editing technology. The new therapy leverages the latest advances in medical science to alleviate the severe painful vaso-occlusive crises (VOCs) associated with sickle cell disease, in a long-awaited step toward equity for a disproportionally impacted Black patient population.

Key Points: 
  • BOSTON, Dec. 8, 2023 /PRNewswire/ -- Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will offer the first-ever gene therapy treatment program for sickle cell disease that uses a type of novel genome editing technology.
  • The announcement comes as the FDA today granted approval of this new therapy, jointly developed by Boston-based Vertex Pharmaceuticals and CRISPR Therapeutics of Switzerland, along with approval of another cell-based gene therapy for sickle cell disease.
  • BMC is the only hospital in New England to offer the Vertex Pharmaceuticals and CRISPR Therapeutics therapy to eligible adults with sickle cell disease.
  • "Boston Medical Center has a longstanding commitment to providing advanced clinical care to those with sickle cell disease," said Dr. Jean-Antoine Ribeil, MD, PhD, Clinical Director of the Center of Excellence in Sickle Cell Disease at Boston Medical Center and an internationally renowned hematologist who has dedicated his career to the development of gene therapies for patients with sickle cell disease and beta thalassemia.

Jacksonville, FL Pulmonologists Join First Coast Cardiovascular Institute

Retrieved on: 
Friday, December 1, 2023

JACKSONVILLE, Fla., Dec. 1, 2023 /PRNewswire-PRWeb/ -- First Coast Cardiovascular Institute (FCCI) welcomes two pulmonologists, Dr. Jack Salah and Dr. Stephen Bagnoli, to its team.

Key Points: 
  • First Coast Cardiovascular Institute (FCCI) welcomes two pulmonologists, Dr. Jack Salah and Dr. Stephen Bagnoli, to its team.
  • JACKSONVILLE, Fla., Dec. 1, 2023 /PRNewswire-PRWeb/ -- First Coast Cardiovascular Institute (FCCI) welcomes two pulmonologists, Dr. Jack Salah and Dr. Stephen Bagnoli, to its team.
  • Dr. Jack Salah is board certified in internal medicine, pulmonary medicine, and critical care medicine.
  • "We are excited to join with FCCI and Cardiovascular Logistics.

As Lung Cancer Rates Continue to Rise in Never-Smokers, Theator Expands Surgical Solution into Thoracic Surgery

Retrieved on: 
Thursday, November 16, 2023

PALO ALTO, Calif., Nov. 16, 2023 /PRNewswire/ -- Theator, a health-technology company that leverages advanced AI and computer vision technology to help surgeons and hospitals improve the quality of patient care, today announced that it will be expanding its Surgical Intelligence Platform into the field of thoracic surgery.  Despite there being over 530,000 thoracic procedures conducted in the US each year, the surgical specialty is facing a major deficit of cardiothoracic surgeons. With lung cancer continuing to be on the rise in never-smokers, Theator's award-winning technology will help hospitals meet the growing demand for minimally invasive thoracic surgeries by providing surgeons in the OR with the actionable insights they need to not only address but also up-level patient care across the board.

Key Points: 
  • Despite there being over 530,000 thoracic procedures conducted in the US each year, the surgical specialty is facing a major deficit of cardiothoracic surgeons.
  • "At Theator, we are focused on generating actionable insights to positively impact patient outcomes and improve the quality of patient care," said Dr. Tamir Wolf, co-founder and CEO of Theator.
  • "Currently, there are limited ways for surgeons to access actionable and reliable evaluations of thoracic surgical performance," said Dr. Matthew Ninan, Director of Thoracic Surgery at HCA Florida Healthcare West Division.
  • For more information about Theator's Surgical Intelligence Platform and its expansion into the field of thoracic, please visit www.theator.io .

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC

Retrieved on: 
Wednesday, November 1, 2023

ET

Key Points: 
  • ET
    EMERYVILLE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a genetic medicines company with three novel, highly targeted next generation AAV vectors currently in human clinical studies, today announced interim data from the Phase 1/2 AEROW clinical trial evaluating aerosolized 4D-710 for treatment of cystic fibrosis lung disease.
  • Results will also be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) in both plenary and symposium sessions on November 2-3.
  • “We are pleased with the safety and tolerability of 4D-710 in participants in the AEROW study to date.
  • Initial results from the AEROW study showed that 4D-710 resulted in CFTR expression in lung airways that significantly exceeded our target profile.

bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales

Retrieved on: 
Monday, November 6, 2023

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dallas J. Coleman as National Director of Sales.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dallas J. Coleman as National Director of Sales.
  • Mr. Coleman has more than 15 years of experience in medical sales and marketing, most recently as Executive Account Manager for the respiratory portfolio of Olympus America’s therapeutic solutions division.
  • Reporting to bioAffinity Technologies President and Chief Executive Officer Maria Zannes, Mr. Coleman is responsible for leading the CyPath® Lung sales team and sourcing new business opportunities.
  • “We are delighted to welcome Dallas to our management team in this newly created position.

American Association for Respiratory Care Honors Tri-anim Health Services with 2023 Zenith Award

Retrieved on: 
Monday, October 30, 2023

DUBLIN, Ohio , Oct. 30, 2023 /PRNewswire/ -- Tri-anim Health Services, a Sarnova company and a leading distributor of specialized respiratory, anesthesia, and critical care supplies, services and equipment, has been honored with the prestigious 2023 Zenith Award by the American Association for Respiratory Care (AARC).

Key Points: 
  • DUBLIN, Ohio , Oct. 30, 2023 /PRNewswire/ -- Tri-anim Health Services, a Sarnova company and a leading distributor of specialized respiratory, anesthesia, and critical care supplies, services and equipment, has been honored with the prestigious 2023 Zenith Award by the American Association for Respiratory Care (AARC).
  • This marks the fifth time that Tri-anim has won the Zenith Award (2023, 2021, 2020, 2018, and 2017).
  • The AARC Zenith Award is the "people's choice" award of the respiratory care profession because its recipients are chosen and voted upon by caregivers – the respiratory therapists.
  • Since 1975, Tri-anim has served as a specialty healthcare consultant and distributor of respiratory care, anesthesia, critical care and neonatal care supplies and equipment.

ConcertAI's TeraRecon partners with Optellum to integrate AI-powered early lung cancer diagnosis and precision treatment planning

Retrieved on: 
Tuesday, October 17, 2023

CAMBRIDGE, Mass., Oct. 17, 2023 /PRNewswire/ -- ConcertAI's TeraRecon, the advanced visualization and clinical AI SaaS company, announced today its strategic collaboration with Optellum Ltd (Oxford, UK), a global leader in AI clinical decision support for early lung cancer diagnosis and precision treatment planning.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 17, 2023 /PRNewswire/ -- ConcertAI's TeraRecon, the advanced visualization and clinical AI SaaS company, announced today its strategic collaboration with Optellum Ltd (Oxford, UK), a global leader in AI clinical decision support for early lung cancer diagnosis and precision treatment planning.
  • Lung cancer often shows no symptoms until a late stage when treatment options are more limited and outcomes less positive.
  • TeraRecon's collaboration with Optellum marks a significant milestone in advancing lung cancer diagnosis and aiding thoracic oncology teams in treatment," said Jeff Elton, PhD, CEO of ConcertAI.
  • In the ESMO scientific program, Optellum's clinical partners will present the first results towards extending the LCP platform into AI-guided precision treatment in the "NSCLC, Early Stage".